![Thomas Sabia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profilo
Thomas Sabia formerly worked at Quince Therapeutics SpA, as Chief Commercial Officer from 2022 to 2023 and Quince Therapeutics, Inc., as Chief Commercial Officer from 2022 to 2025.
Mr. Sabia received his undergraduate degree and Masters Business Admin degree from Salisbury State University.
Precedenti posizioni note di Thomas Sabia
| Società | Posizione | Fine |
|---|---|---|
| QUINCE THERAPEUTICS, INC. | Corporate Officer/Principal | 28/02/2025 |
EryDel SpA
 EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Corporate Officer/Principal | 01/10/2023 |
Formazione di Thomas Sabia
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
6
Relazioni di 1° grado
3
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Salisbury State University
 Salisbury State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EryDel SpA
EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Health Technology |
Quince Therapeutics, Inc.
 Quince Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops drugs for the treatment of central nervous system disorders and Alzheimer’s diseases | Health Technology |
